A Phase II Study of Sorafenib and Bevacizumab in Epithelial Ovarian, Fallopian, and Peritoneal Cancer.
Phase of Trial: Phase II
Latest Information Update: 01 Sep 2017
At a glance
- Drugs Sorafenib (Primary) ; Bevacizumab
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- 08 Sep 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 01 Nov 2013 Planned end date changed from 1 Oct 2013 to 1 Oct 2014 as reported by ClinicalTrials.gov.
- 25 Mar 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.